The combination of Pembro and standard chemotherapy (pemetrexed and a platinum‐based drug) has been approved by the United States Food and Drug Administration (FDA) May 201714 and National Medical Products Administration (NMPA) in China in March 2019 as the first‐line therapy for patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.